NO310871B1 - Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi - Google Patents

Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi Download PDF

Info

Publication number
NO310871B1
NO310871B1 NO19983632A NO983632A NO310871B1 NO 310871 B1 NO310871 B1 NO 310871B1 NO 19983632 A NO19983632 A NO 19983632A NO 983632 A NO983632 A NO 983632A NO 310871 B1 NO310871 B1 NO 310871B1
Authority
NO
Norway
Prior art keywords
modification
compound
formula
water
mixtures
Prior art date
Application number
NO19983632A
Other languages
English (en)
Norwegian (no)
Other versions
NO983632D0 (no
NO983632L (no
Inventor
Holger Faasch
Udo Hedtmann
Uwe Westenfelder
Erich Paulus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO983632D0 publication Critical patent/NO983632D0/no
Publication of NO983632L publication Critical patent/NO983632L/no
Publication of NO310871B1 publication Critical patent/NO310871B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19983632A 1997-08-08 1998-08-07 Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi NO310871B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (3)

Publication Number Publication Date
NO983632D0 NO983632D0 (no) 1998-08-07
NO983632L NO983632L (no) 1999-02-09
NO310871B1 true NO310871B1 (no) 2001-09-10

Family

ID=26038983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983632A NO310871B1 (no) 1997-08-08 1998-08-07 Krystallform av (N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4- karboksamid), fremgangsmåte for fremstilling av denne, legemiddelinneholdende denne, samt anvendelse av krystallformen og enfremgangsmåte for fremstilling av modifikasjon 1 av forbi

Country Status (28)

Country Link
US (5) US6060494A (cg-RX-API-DMAC7.html)
EP (2) EP0903345B1 (cg-RX-API-DMAC7.html)
JP (2) JPH11124372A (cg-RX-API-DMAC7.html)
KR (2) KR100544041B1 (cg-RX-API-DMAC7.html)
CN (2) CN1181064C (cg-RX-API-DMAC7.html)
AR (1) AR015418A1 (cg-RX-API-DMAC7.html)
AT (2) ATE207065T1 (cg-RX-API-DMAC7.html)
AU (1) AU752764B2 (cg-RX-API-DMAC7.html)
BR (1) BR9806568A (cg-RX-API-DMAC7.html)
CA (1) CA2245267C (cg-RX-API-DMAC7.html)
CZ (3) CZ301426B6 (cg-RX-API-DMAC7.html)
DE (2) DE59800287D1 (cg-RX-API-DMAC7.html)
DK (2) DK0903345T3 (cg-RX-API-DMAC7.html)
ES (2) ES2166205T3 (cg-RX-API-DMAC7.html)
GR (1) GR3034814T3 (cg-RX-API-DMAC7.html)
HK (1) HK1049481B (cg-RX-API-DMAC7.html)
HU (2) HU225870B1 (cg-RX-API-DMAC7.html)
ID (1) ID20667A (cg-RX-API-DMAC7.html)
IL (1) IL125671A (cg-RX-API-DMAC7.html)
NO (1) NO310871B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ331270A (cg-RX-API-DMAC7.html)
PL (1) PL192126B1 (cg-RX-API-DMAC7.html)
PT (2) PT987256E (cg-RX-API-DMAC7.html)
RU (1) RU2224753C2 (cg-RX-API-DMAC7.html)
SK (2) SK282641B6 (cg-RX-API-DMAC7.html)
TR (2) TR200600582A1 (cg-RX-API-DMAC7.html)
TW (1) TW593288B (cg-RX-API-DMAC7.html)
UA (1) UA54411C2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US7022725B2 (en) * 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
LT2262790T (lt) * 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
GB9115377D0 (en) * 1991-07-17 1991-09-04 Rhone Poulenc Agriculture New compositions of matter
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (cg-RX-API-DMAC7.html) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
ID20667A (id) 1999-02-11
DK0903345T3 (da) 2000-10-23
RU2224753C2 (ru) 2004-02-27
CN1373126A (zh) 2002-10-09
US6552202B2 (en) 2003-04-22
TR200600582A1 (tr) 2006-08-21
CZ292943B6 (cs) 2004-01-14
KR100544041B1 (ko) 2006-09-18
PL192126B1 (pl) 2006-09-29
CN1089759C (zh) 2002-08-28
ATE207065T1 (de) 2001-11-15
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
DE59801792D1 (de) 2001-11-22
HU0700190D0 (en) 2007-05-02
TR199801513A3 (tr) 1999-02-22
DE59800287D1 (de) 2000-11-09
ES2150808T3 (es) 2000-12-01
HUP9801844A3 (en) 2000-04-28
AU7887098A (en) 1999-02-18
CA2245267A1 (en) 1999-02-08
HU229232B1 (en) 2013-09-30
US6900334B2 (en) 2005-05-31
HU225870B1 (en) 2007-11-28
HU9801844D0 (en) 1998-10-28
CZ301514B6 (cs) 2010-03-31
US20030027851A1 (en) 2003-02-06
ATE196764T1 (de) 2000-10-15
SK285216B6 (sk) 2006-09-07
CA2245267C (en) 2008-12-23
TR199801513A2 (xx) 1999-02-22
PT987256E (pt) 2002-03-28
KR100588254B1 (ko) 2006-06-12
NO983632D0 (no) 1998-08-07
US20030166945A1 (en) 2003-09-04
HUP9801844A2 (hu) 2000-02-28
KR19990023433A (ko) 1999-03-25
KR20050077498A (ko) 2005-08-02
UA54411C2 (uk) 2003-03-17
PT903345E (pt) 2001-01-31
PL327901A1 (en) 1999-02-15
EP0987256A1 (de) 2000-03-22
IL125671A0 (en) 1999-04-11
CN1181064C (zh) 2004-12-22
CZ301426B6 (cs) 2010-02-24
BR9806568A (pt) 2000-05-16
EP0987256B1 (de) 2001-10-17
DK0987256T3 (da) 2002-02-11
CZ246898A3 (cs) 1999-02-17
ES2166205T3 (es) 2002-04-01
US6995272B2 (en) 2006-02-07
HK1017681A1 (en) 1999-11-26
SK105898A3 (en) 1999-02-11
CN1208034A (zh) 1999-02-17
US6060494A (en) 2000-05-09
US6221891B1 (en) 2001-04-24
SK282641B6 (sk) 2002-10-08
JP2009280604A (ja) 2009-12-03
EP0903345A1 (de) 1999-03-24
AR015418A1 (es) 2001-05-02
AU752764B2 (en) 2002-09-26
EP0903345B1 (de) 2000-10-04
HK1049481A1 (en) 2003-05-16
JPH11124372A (ja) 1999-05-11
IL125671A (en) 2002-11-10
HK1049481B (zh) 2005-07-08
NO983632L (no) 1999-02-09
TW593288B (en) 2004-06-21
GR3034814T3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
AU752764B2 (en) Crystal form of N-(4-trifluoromethylphenyl)-5- methylisoxazole-4-carboxamide
HU196775B (en) Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
CN114174284A (zh) 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的结晶盐形式
CN106795159A (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
EP0142309B1 (en) Method of preparing steroid compoundshaving a reduced particle size form
CN107739358B (zh) 一种大豆苷元无水晶型ii、制备方法及其医药用途
CN106866666B (zh) 一种帕博西尼晶型化合物及其制备方法
WO2016101412A1 (zh) 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用
CA2531948C (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
CN103709156B (zh) 一种达沙替尼多晶型药物及其制备方法
EP3004104A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
HK1017681B (en) Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox
CN115746004A (zh) 一种阿普唑仑一水合物晶型及其制备方法

Legal Events

Date Code Title Description
MK1K Patent expired